Drugs / IN-B009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05113849 | Sep 2021 → Feb 2023 | COVID-19 | HK inno.N Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN-B009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05113849 ↗ |
| Modality | Vaccine | “SARS-CoV-2 Vaccine (IN-B009)” NCT05113849 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05113849 ↗ |